Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | CCR1 | P32246 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1341511 | 0.79 | SLC40A1 (0.55) | KDM4ELMNAMAPTTDP1MMP2 | |
| SCHEMBL29398699 | 0.79 | SLC40A1 (0.55) | KDM4ELMNAMAPTTDP1MMP2 | |
| SCHEMBL737516 | 0.79 | KDM4E (0.54) | KDM4ELMNAMAPTTDP1MMP2 | |
| SCHEMBL4175358 | 0.79 | KDM4E (0.54) | KDM4ELMNAMAPTTDP1MMP2 | |
| SCHEMBL2012290 | 0.79 | KDM4E (0.43) | KDM4ELMNAMAPTTDP1MMP2 | |
| Hydrochloric Acid SCHEMBL27976997 | 0.78 | SLC40A1 (0.54) | KDM4ELMNAMAPTTDP1MMP2 | |
| SCHEMBL6852161 | 0.77 | KDM4E (0.47) | KDM4ELMNAMAPTTDP1MMP2 | |
| SCHEMBL6852617 | 0.76 | KDM4E (0.50) | KDM4ELMNAMAPTTDP1MMP2 | |
| SCHEMBL2007370 | 0.76 | MMP2 (0.31) | KDM4ELMNAMAPTTDP1MMP2 | |
| SCHEMBL11966088 | 0.76 | KDM4E (0.50) | KDM4ELMNAMAPTTDP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | US | claimed |
| EP-0788360-B3 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARM INC (US) | 2009-08-12 | — | — | EP | claimed |
| US-6967197-B2 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-22 | — | — | US | claimed |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | US | claimed |
| EP-0788360-B1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARM INC (US) | 2003-05-28 | — | — | EP | claimed |
| WO-2003018019-A2 | NEW USE OF CYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | WO | claimed |
| EP-1259499-A1 | THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | claimed |
| WO-2001060808-A1 | THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | claimed |
| EP-0827507-B1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM CA LTD (CA) | 1999-06-16 | — | — | EP | claimed |
| EP-0788360-A4 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT INC (US) | 1998-05-06 | — | — | EP | claimed |
| EP-0827507-A1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1998-03-11 | — | — | EP | claimed |
| EP-0788360-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1997-08-13 | — | — | EP | claimed |
| WO-1996031527-A1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD./BOEHRINGER INGELHEIM (CANADA) LTÉE. (CA) | 1996-10-10 | — | — | WO | claimed |
| US-5545640-A | VIRICIDES, HIV; AIDS | BIO-MEGA/BOEHRINGER INGELEHEIM RESEARCH INC. (CA) | 1996-08-13 | — | — | US | claimed |
| WO-1996013266-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1996-05-09 | — | — | WO | claimed |
| US-5017212-A | For rice paddies | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-05-21 | — | — | US | claimed |
| US-20240148916-A1 | BIVALENT FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2024-05-09 | — | — | US | disclosed |
| WO-2024052333-A1 | MULTIVALENT FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2024-03-14 | — | — | WO | disclosed |
| EP-0305939-A1 | Process of producing sulfonylurea derivatives | Takeda Chemical Industries, Ltd. (JP) | 1989-03-08 | — | — | EP | disclosed |
| EP-0238070-A2 | Sulfonylurea compounds, their production and herbicidal use | Takeda Chemical Industries, Ltd. (JP) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | KDM4E 3575/4885LMNA 3434/4885MAPT 4135/4885 |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | MMP9, MMP1, MMP3 | KDM4E 2518/4885LMNA 1391/4885MAPT 4811/4885 |
| US-20240148916-A1 | BIVALENT FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | FAP, FIBP, FGFR2 | KDM4E 3620/4885LMNA 3765/4885MAPT 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.